Hypersexuality across neurological disorders: A systematic review of aetiologies, clinical manifestations, assessment methods, and management strategies.

Neurosci Biobehav RevJun 22, 2026 (epub)
Clinical ResearchNeurology

Alexa Schincariol, Rachele Pezzetta, Maria Devita et al.

✦ AI-curated · Sources linked

In 30 seconds

This systematic review analyzed 394 studies involving 46,516 participants to explore hypersexuality (HY) in neurological disorders. The majority of cases (≈61%) were iatrogenic, primarily linked to dopaminergic therapy in Parkinson's disease. The review highlights the need for improved assessment and management strategies for this under-recognized behavioral complication.

Key findings

  • Approximately 61% of hypersexuality cases were iatrogenic, mainly due to dopaminergic therapy in Parkinson's disease.
  • About 25% of cases were acquired from focal lesions, traumatic brain injury, or neurodegenerative syndromes.
  • Nearly half of the studies relied solely on unstructured notes for assessment.
  • Less than 10% of studies formally consulted informants for assessment.

Why it matters

Hypersexuality is a significant behavioral complication in neurological disorders that can impact patient quality of life and caregiver burden. Understanding its aetiology and management is crucial for effective clinical practice.

Source

Published in Neurosci Biobehav Rev. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Neurology

Clinical ResearchOncology (Medical)

Zamtocabtagene autoleucel, a tandem CD20-CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 study.

DALY 2-EU was an open-label, multicentre, randomised phase 2 trial comparing tandem CD20-CD19-directed zamtocabtagene autoleucel (zamto-cel) with R-GemOx in adults with second-line relapsed or refractory large B-cell…

Lancet OncolOct 27, 2026Read summary
Clinical ResearchOncology (Medical)

Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trial.

UNION was a multicentre, open-label, randomised phase 3 trial at nine hospitals in China comparing neoadjuvant short-course radiotherapy followed by camrelizumab plus CAPOX with long-course chemoradiotherapy followed by…

Lancet OncolOct 25, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.